ArticleJournal of bacteriology2020
Nanoluciferase Reporter Mycobacteriophage for Sensitive and Rapid Detection of Mycobacterium tuberculosis Drug Susceptibility.
Open access · hybridAbstract read
In one paragraph
Article in Journal of bacteriology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Development and clinical validation of a CRISPR/Cas9-engineered reporter phage cocktail for rapid detection ofMicrobiology spectrum · 2026Article
- Rapid detection of treatment-emergent resistance to bedaquiline and pretomanid inMicrobiology spectrum · 2026Article
- Rapid drug susceptibility testing of Mycobacterium tuberculosis against first-line drugs simultaneously all-in-one plate by using a novel high-sensitive reporter phage combined with the BACTEC MGIT 960 system.Infectious diseases of poverty · 2026Article
- Real-time bioluminescence imaging of mycobacteria with Akaluc: a novel method for monitoring drug efficacy.Scientific reports · 2026Article
- The unique role ofmBio · 2026Article
- Advances in mycobacteriophage research: from lytic mechanisms to one health applications.Frontiers in cellular and infection microbiology · 2026Review
- CRISPR-Cas9 enables efficient genome engineering of the strictly lytic, broad-host-range staphylococcal bacteriophage K.Applied and environmental microbiology · 2025Article
- Luciferase reporter mycobacteriophage (TM4::Journal of clinical microbiology · 2025Article
- Mycobacteriophage-mediated gene transfer enables in vitro drug screening and in vivo tracking ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates.The Journal of infectious diseases · 2025Article
- Rapid detection of drug resistance inFrontiers in cellular and infection microbiology · 2025Article
- Development of a Replication-Deficient Bacteriophage Reporter Lacking an Essential Baseplate Wedge Subunit.Viruses · 2023Article
- Biological role of the major AP (abasic site) endonuclease of an archaeon from geothermal environments.Extremophiles : life under extreme conditions · 2022Article
- A Review on Mycobacteriophages: From Classification to Applications.Pathogens (Basel, Switzerland) · 2022Review
- Isolation and engineering of a Listeria grayi bacteriophage.Scientific reports · 2021Article
- Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis.International journal of molecular sciences · 2021Review
- Screening of Fungi for Antimycobacterial Activity Using a Medium-Throughput Bioluminescence-Based Assay.Frontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Paras JainIntellectual Ventures Laboratory, Bellevue, Washington, USA parasjain29@gmail.com kyle.minch@ghlabs.org.
Spencer GaringIntellectual Ventures Laboratory, Bellevue, Washington, USA.
Deepshikha VermaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Rajagopalan SaranathanDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Nicholas Clute-ReinigIntellectual Ventures Laboratory, Bellevue, Washington, USA.
Jacob GadwaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Chelsea PetersonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Gleda HermanskyIntellectual Ventures Laboratory, Bellevue, Washington, USA.
Anna Astashkina FernandezIntellectual Ventures Laboratory, Bellevue, Washington, USA.
Emmanuel AsareDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Torin R WeisbrodDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Ethan SpencerIntellectual Ventures Laboratory, Bellevue, Washington, USA.
Claire V MulhollandDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Michael BerneyDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
David BellIntellectual Ventures' Global Good Fund, Bellevue, Washington, USA.
Kevin P NicholsIntellectual Ventures Laboratory, Bellevue, Washington, USA.
Anne-Laure M Le NyIntellectual Ventures Laboratory, Bellevue, Washington, USA.
Diane OrdwayMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
William R JacobsDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0003-3321-3080
Akos SomoskoviIntellectual Ventures' Global Good Fund, Bellevue, Washington, USA.
Kyle J MinchIntellectual Ventures Laboratory, Bellevue, Washington, USA parasjain29@gmail.com kyle.minch@ghlabs.org.ORCID 0000-0003-2447-5759
Bellevue Hospital Center · USAlbert Einstein College of Medicine · USColorado State University · USIntellectual Ventures (United States) · USTrudeau Institute · US
Funding
Molecular Genetic Analysis of Mycobacterium TuberculosisR37AI026170 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI WILLIAM Robert JACOBS · 2004 to 2026
$7.7MNIAID NIH HHS R37 AI026170
Abstract
Phenotypic testing for drug susceptibility of
Indexed as
Drug Resistance, BacterialAntitubercular AgentsHumansLuciferasesLuminescent MeasurementsMicrobial Sensitivity TestsMycobacteriophagesMycobacterium tuberculosisRifampinTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryAntitubercular AgentsLuciferasesRifampinbacteriophagesdrug screeningdrug susceptibility testingMycobacterium tuberculosisnanoluciferasephage
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.